<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="an underdiagnosed and undertreated condition worldwide [ 2, 8], and" exact="Italy" post="is no exception [ 9, 10]. Migraine has been"/>
 <result pre="Within Europe, prophylactic treatment appears to be particularly underused in" exact="Italy" post="[ 10]. This review summarises strategies for the prophylactic"/>
 <result pre="in the EU [ 46]. OBT-A has been available in" exact="Italy" post="since 2013, where it has the highest level of"/>
 <result pre="in these indications [ 73, 77]. Chronic migraine management in" exact="Italy" post="On the basis of the results of a worldwide"/>
 <result pre="patient (considering healthcare provider visits, hospitalisations, procedures and medications) in" exact="Italy" post="was estimated to be €2648 versus €828 for EM"/>
 <result pre="Health Service (NHS) [ 79]. Current problems CM management in" exact="Italy" post="is largely inadequate and expensive because of clinical and"/>
 <result pre="of clinical and operational issues. Currently, patients with CM in" exact="Italy" post="are managed at tertiary referral headache centres, but long"/>
 <result pre="mean that the true prevalence and cost of CM in" exact="Italy" post="is not known. It is also apparent that a"/>
 <result pre="of patients with CM do not receive prophylactic therapy in" exact="Italy" post="[ 9, 10, 79]. In Italy, physicians may prescribe"/>
 <result pre="high level of multidisciplinary care. Going forward, patient profiles in" exact="Italy" post="will be recorded on a national CM register, which"/>
 <result pre="J Headache Pain. 2017 18 1 96 10.1186/s10194-017-0807-1 28948500 58." exact="Israel" post="H Neeb L Reuter U CGRP monoclonal antibodies for"/>
 <result pre="A pilot study from a tertiary headache centre in Northern" exact="Italy" post="J Headache Pain 2015 16 532 10.1186/s10194-015-0532-6 26018292 80."/>
</results>
